Taken together, our results demonstrated that miR-328-3p enhanced migration and invasion of HNSCC through targeting H2AFX and activated the mTOR pathway, which may be a potential therapeutic target in the treatment of HNSCC patients. Here, H2AX is linked to head and neck squamous cell carcinoma.